You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

1612 Results
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
The Canada Post service disruption may affect the delivery of cancer screening letters and fecal immunochemical test (FIT) kits for colorectal...
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
This page lists cancer resources to support First Nations, Inuit, Métis and urban Indigenous communities and organizations in Ontario. Find tools,...
Cette page présente une liste des ressources sur le cancer visant à aider les collectivités et les organismes des Premières Nations, des Inuits, des...
Drug
Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™
Dec 1969
Drug
Other Name(s): Rituxan® SC
Dec 1969
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma

Pages